News
Novo Nordisk: Is the Ozempic Hype Train Finally Slowing Down?
Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug Wegovy, going down from May’s 21% growth projection to just a 14% sales increase throughout 2025.
Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
U.S.-listed shares of Novo Nordisk (NVO) sank roughly 20% in premarket trading after the Danish drugmaker cut its full-year ...
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.
Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback